<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060914</url>
  </required_header>
  <id_info>
    <org_study_id>ANZHEN HOSPITOL-LY-01</org_study_id>
    <nct_id>NCT04060914</nct_id>
  </id_info>
  <brief_title>LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention</brief_title>
  <acronym>LOTIC</acronym>
  <official_title>LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis in this study was that ticagrelor switched to 60 mg after 1 month of standard
      dose, with antiplatelet activity that is not inferior to the standard dose and better than 75
      mg clopidogrel for patients with ACS after PCI.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity index (PRI)</measure>
    <time_frame>90 days (±14)</time_frame>
    <description>Platelet reactivity of ticagrelor or clopidogrel MD will be measured as PRI% using whole blood vasodilator-stimulated phosphoprotein (VASP) at 90 days after PCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of main adverse cardiovascular and cerebrovascular events (MACCE)</measure>
    <time_frame>1 year</time_frame>
    <description>MACCE includes all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The platelet aggregation ratio</measure>
    <time_frame>90 days (±14)</time_frame>
    <description>Platelet aggregation of ticagrelor or clopidogrel MD will be measured using the Light Transmittance Aggregometry method at day 90 after PCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma adenosine concentration</measure>
    <time_frame>90 days (±14)</time_frame>
    <description>Plasma adenosine concentration in the three treatment groups will be measured using the HPLC-MS at day 90 after PCI.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Antiplatelet Therapy</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Ticagrelor(90mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor(90/60mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel(75mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg</intervention_name>
    <description>Ticagrelor 90 mg plus aspirin for 12 months</description>
    <arm_group_label>Ticagrelor(90mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg/60mg</intervention_name>
    <description>1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months</description>
    <arm_group_label>Ticagrelor(90/60mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75mg</intervention_name>
    <description>Clopidogrel 75mg plus aspirin for 12 months</description>
    <arm_group_label>Clopidogrel(75mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agree to sign the Informed Consent;

          -  Male or female, ≥ 18 years of age, and ≤ 70 years of age

          -  Patient presents with acute coronary syndrome (ACS)

          -  Planned to undergo PCI

          -  Planned to DAPT for 1 year after PCI

        Exclusion Criteria:

          -  Treatment with other investigational agents (including placebo) or devices within 30
             days prior to randomization or planned use of investigational agents or devices prior
             to the Day 30 visit.

          -  Patients cannot use ticagrelor or clopidogrel due to contraindications or other
             reasons.

          -  Patients with active pathological hemorrhage or a history of intracranial hemorrhage

          -  Patient unable to receive 12 months of dual anti-platelet therapy

          -  Patient developing procedure-related complications such as stent thrombosis, coronary
             dissection, coronary perforation, cardiac tamponade or no-reflow during PCI

          -  Patient or physician refusal to enroll in the study

          -  History of intracranial hemorrhage

          -  Patient has a history of bleeding diathesis or coagulopathy

          -  Patient has an active pathological bleeding, such as active gastrointestinal (GI)
             bleeding

          -  Patient is pregnant, breastfeeding, or planning to become pregnant within 12 months

          -  Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist,
             direct thrombin inhibitor, Factor Xa inhibitor)

          -  Patient with cardiogenic shock or mechanical circulatory assist devices placed

          -  Patient with active liver diseases

          -  Patient with severe renal insufficiency (eGFR &lt;30ml/min/1.73m2 based on simplified
             MDRD equation or CrCl &lt;30ml/min based on Cockcroft-Gault equation)

          -  Patient has a malignancy or a life expectancy of less than one year

          -  Platelet count &lt;100 000/μL, or hematocrit &lt;32% or &gt;52%, or white blood cell count
             &lt;3000/μL

          -  Any other condition deemed by the investigator to place the patient at excessive risk
             of bleeding with ticagrelor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yi Zhang, PhD</last_name>
    <phone>86-010-64456609</phone>
    <email>phd-zhangyi@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Lin, PhD</last_name>
    <phone>86-010-64456609</phone>
    <email>linyang3623@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Lin, PhD</last_name>
      <phone>86-010-64456609</phone>
      <email>linyang3623@outlook.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiujing Shi, MD</last_name>
      <phone>86-010-64456609</phone>
      <email>xiujingshi@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Lin Yang</investigator_full_name>
    <investigator_title>PHD</investigator_title>
  </responsible_party>
  <keyword>ticagrelor</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Adenosine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

